Niagen Bioscience, Inc.
NAGE
$6.76
$0.223.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6,197.37% | 295.83% | 99.32% | 74.13% | 108.04% |
| Total Depreciation and Amortization | -4.02% | -18.30% | -16.67% | -11.36% | -18.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -478.49% | -43.72% | -31.38% | -35.40% | -21.83% |
| Change in Net Operating Assets | 660.42% | 219.19% | -156.49% | -124.32% | -23.41% |
| Cash from Operations | 1,222.50% | 782.58% | -108.05% | -89.43% | 297.87% |
| Capital Expenditure | -228.57% | -57.69% | -20.00% | 54.95% | 87.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -228.57% | 19.23% | -140.00% | 54.95% | 87.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00% | -33.33% | 80.00% | -200.00% | 83.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.33% | -- | -- | -- | -20.97% |
| Cash from Financing | 5,031.58% | 34,733.33% | 6,060.00% | -1,300.00% | -100.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,121.38% | 1,129.70% | -90.20% | -91.11% | -92.31% |